Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP).
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
You may not be if
Not applicable.
Clareo Health | Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
